Hepatitis B- Hepatitis B- what GI what GI nurses Need to Know nurses Need to Know Mary Pat Pauly MD Mary Pat Pauly MD Gastroenterology and Hepatology Gastroenterology and Hepatology Kaiser Permanente Kaiser Permanente Clinical Professor of Internal Medicine Clinical Professor of Internal Medicine and GI and GI at UC Davis at UC Davis
53
Embed
Hepatitis B- what GI nurses Need to Know Mary Pat Pauly MD Gastroenterology and Hepatology Kaiser Permanente Clinical Professor of Internal Medicine and.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Hepatitis B- Hepatitis B- what GI nurses what GI nurses Need to KnowNeed to Know
Mary Pat Pauly MDMary Pat Pauly MDGastroenterology and Hepatology Gastroenterology and Hepatology
Kaiser Permanente Kaiser Permanente Clinical Professor of Internal Medicine and GI Clinical Professor of Internal Medicine and GI
at UC Davisat UC Davis
Hepatitis B Hepatitis B
EpidemiologyEpidemiologyModes of transmissionModes of transmissionHepatitis B vaccineHepatitis B vaccineNatural History Natural History Interpretation of serologyInterpretation of serologyIndications for treatment Indications for treatment Newer drugs available for treatmentNewer drugs available for treatmentImportance of Importance of ongoing follow up ongoing follow up
Hepatitis B Hepatitis B
EpidemiologyEpidemiology– Modes of Modes of
transmissiontransmissionRole of Hepatitis B vaccineRole of Hepatitis B vaccineNatural History Natural History Interpretation of serologyInterpretation of serologyIndications for treatment Indications for treatment Newer drugs available for Newer drugs available for treatmenttreatmentImportance of Importance of ongoing follow up ongoing follow up
Global Impact of Hepatitis BGlobal Impact of Hepatitis B
World PopulationWorld Population6 billion6 billion
2 billion with past / present 2 billion with past / present HBV infectionHBV infection
350–400 million with 350–400 million with chronic hepatitis Bchronic hepatitis B
or hepatocellular or hepatocellular carcinomacarcinoma
Worldwide: Worldwide: ~1 million / year die from HBV-associated liver disease ~1 million / year die from HBV-associated liver disease
United States: United States: Chronically infected ~1.25 million; ~5000 / year dieChronically infected ~1.25 million; ~5000 / year die
Korean Mummy Found With Korean Mummy Found With HBVHBV
Virus discovered in the Virus discovered in the liver of the South Korean liver of the South Korean Handong mummy Handong mummy – 500-year-old child500-year-old child– First time HBV ever been First time HBV ever been
found in a mummified body found in a mummified body
Study of the genome of Study of the genome of the 500-year-old virus the 500-year-old virus under way under way – To see if there have been To see if there have been
any significant changes to any significant changes to HBV over timeHBV over time
Prevalence of HBV in immigrant Prevalence of HBV in immigrant populationspopulations
Prevalence reflects Prevalence reflects pattern of infection pattern of infection in country of originin country of origin– Africa 10 – 15%Africa 10 – 15%– Asia 10.4%Asia 10.4%– Eastern Europe 2-7%Eastern Europe 2-7%
Survey of Asian Am Survey of Asian Am populationspopulations– 23% in NYC*23% in NYC*– 11.1% in Chicago**11.1% in Chicago***Sherman A et al. Hepatology 2005;42:
214A**Cotler S et al. Clin Gastro & Hep 2009;7:776-80
Chronic HBV Prevalence: Asian Chronic HBV Prevalence: Asian Americans in San Francisco (2001-Americans in San Francisco (2001-
2006)2006)
Lin SY, et al Hepatology. 2007;46:1034-1040.
Chronic HBVPositive
At Risk: Lack ofProtective Antibodies
8.9%
Chronic HBV Positive,Unaware of Serostatus
65.4%
44.8%
Pre
vale
nce
(%
)
0
30
50
80
40
20
10
60
70
Transmission of HBV Transmission of HBV HBVHBV HCVHCV
IVDAIVDA commoncommon commoncommon
TransfusionTransfusion Before Before 19801980 Before 1992Before 1992
sexualsexual commoncommon uncommonuncommon
MSMMSM commoncommon rarerare
Vertical – mother Vertical – mother to baby to baby
Common Common
> 90% ->chronic > 90% ->chronic diseasedisease
< 5%< 5%
Child Child child child Africa 20 – 30% Africa 20 – 30%
health care workerhealth care worker possiblepossible possiblepossible
28 year old nursing school colleague28 year old nursing school colleague– From TaiwanFrom Taiwan– In USA since age 10In USA since age 10
Applying for job at your hospitalApplying for job at your hospital– She was told to get HBV vaccineShe was told to get HBV vaccine– Requirement Requirement
Hepatitis B vaccine in employees who are not already Hepatitis B vaccine in employees who are not already immune to HBV immune to HBV
she was vaccinated when she went to nursing she was vaccinated when she went to nursing schoolschool– But HBsAB is neg.But HBsAB is neg.
What is your recommendation?What is your recommendation?
Hepatitis B vaccineHepatitis B vaccine
Recommended 3 doses at 0,1 and 6 monthsProtection– 30 – 50% first dose– 75% second dose – 96% with three dose
series
Vaccine is not perfect– Economic barriers– Cultural barriers
Some is better than none….
Protection lower in OlderHIVchronic liver diseases diabetes obesesmokers
Two vaccines availableTwo vaccines available– Energix B – 20 mcgEnergix B – 20 mcg– Recombivax HB – 10 mcgRecombivax HB – 10 mcg
Acute HBV Infection Incidence* Acute HBV Infection Incidence* in the US (1982-2006)in the US (1982-2006)
Universal Universal vaccination vaccination of infants of infants recommended recommended in 1991in 1991
Risk factors for HBV in USRisk factors for HBV in US
other*Non IDMSMIDUHeterosexual
42%42%
18%18%
19%19%
16%16%
5%5%
CDC Sentinel Counties Study 1991-2006CDC Sentinel Counties Study 1991-2006
Case continuedCase continuedCheck further into history Check further into history – No FH of HBVNo FH of HBV
21 year old sister in LA who is healthy and without problems21 year old sister in LA who is healthy and without problems– Family history of mother who died at age 45 from Family history of mother who died at age 45 from
EpidemiologyEpidemiologyModes of transmissionModes of transmissionHepatitis B vaccineHepatitis B vaccineNatural History Natural History
Interpretation of Interpretation of serologyserologyIndications for treatment Indications for treatment Newer drugs available Newer drugs available for treatmentfor treatmentImportance of Importance of ongoing ongoing follow up follow up
Hepatitis B terminologyHepatitis B terminology
There are three proteins expressed by the There are three proteins expressed by the Hepatitis B virusHepatitis B virus
Surface antigenSurface antigen– HBsAgHBsAg
Core antigenCore antigen– HBcAgHBcAg
Envelope antigenEnvelope antigen– HBeAgHBeAg
NameName AbbreviationAbbreviation DefinitionDefinitionHepatitis B Hepatitis B Surface AntigenSurface Antigen HBsAgHBsAg Protein found on the surface of virus, Protein found on the surface of virus,
indicates active infection. indicates active infection.
Hepatitis B Hepatitis B Surface AntibodySurface Antibody HBsAbHBsAb Antibody to the surface protein – confers Antibody to the surface protein – confers
immunity. Can be result of vaccination or immunity. Can be result of vaccination or past infection.past infection.
Hepatitis B Core Hepatitis B Core AntigenAntigen HBcAgHBcAg The core protein is inner structure of the The core protein is inner structure of the
virus and encloses the DNA. Found only in virus and encloses the DNA. Found only in the liver. the liver.
Hepatitis B Core Hepatitis B Core AntibodyAntibody HBcAbHBcAb Antibody to the core antigen is found in Antibody to the core antigen is found in
chronic hepatitis, resolved acute or chronic chronic hepatitis, resolved acute or chronic infection. NOT seen in those immune infection. NOT seen in those immune because of vaccine.because of vaccine.
Hepatitis B e Hepatitis B e AntigenAntigen HBeAgHBeAg This is a soluble protein detected when viral This is a soluble protein detected when viral
titers are high. Correlates with infectivity titers are high. Correlates with infectivity with the “wild type” HBV.with the “wild type” HBV.
Hepatitis B e Hepatitis B e AntibodyAntibody HBeAbHBeAb Antibody to the “e” Antigen. Can be seen in Antibody to the “e” Antigen. Can be seen in
inactive HBV, or chronic active hepatitis inactive HBV, or chronic active hepatitis secondary to a mutant: precore or core secondary to a mutant: precore or core promoter mutant. promoter mutant.
A few other termsA few other terms
ALT ALT alanine amino transferasealanine amino transferase
Our colleague saw a gastroenterologist and had Our colleague saw a gastroenterologist and had additional tests ordered. additional tests ordered. She presents the following to you for interpretation: She presents the following to you for interpretation: – HBeAg positiveHBeAg positive– HBeAb negativeHBeAb negative– ALT 15, AST 16ALT 15, AST 16– Bilirubin, INR and platelet count – normalBilirubin, INR and platelet count – normal– HBV DNA –1,000,000 IU/ml 10 (6)HBV DNA –1,000,000 IU/ml 10 (6)– Alpha feto protein –normalAlpha feto protein –normal– Ultrasound of the liver – normal.Ultrasound of the liver – normal.
See AASLD guidelines – See AASLD guidelines – www.AASLD.org– This is exactly what is suggested in the AASLD guidelines for This is exactly what is suggested in the AASLD guidelines for
the evaluation of patients with HBV. One would also like to do the evaluation of patients with HBV. One would also like to do complete history. Rule out other causes of liver disease such as complete history. Rule out other causes of liver disease such as AIH, HCV and HIV. And hemochromatosis.AIH, HCV and HIV. And hemochromatosis.
Adapted from Lok AS, et al. Hepatology. 2007;45:507-539
The next question she asks The next question she asks
Is she a candidate for treatment?Is she a candidate for treatment?
Hepatitis B Hepatitis B
EpidemiologyEpidemiologyModes of transmissionModes of transmissionRole of Hepatitis B vaccineRole of Hepatitis B vaccineNatural History Natural History Interpretation of serologyInterpretation of serology
Indications for Indications for treatment treatment Newer drugs available for Newer drugs available for treatmenttreatmentImportance of Importance of ongoingongoing
follow upfollow up
Treatment of HBVTreatment of HBVCurrent Recommendations Current Recommendations
Monitor patients in Monitor patients in – Immune tolerant phaseImmune tolerant phase– Inactive –carrier stateInactive –carrier state
Consider treatment Consider treatment – Chronic Active hepatitisChronic Active hepatitis
Wild type – HBeAg positiveWild type – HBeAg positiveMutant type – HBeAg negative and HBeAb positiveMutant type – HBeAg negative and HBeAb positive
TreatTreat– Cirrhosis with active viral replicationCirrhosis with active viral replication
Consider: Consider: – Age, severity of liver disease, likelihood of response, Age, severity of liver disease, likelihood of response,
potential adverse eventspotential adverse events
ccc DNA….ccc DNA….nasty little viral formnasty little viral form
Does not replicateDoes not replicate
Impervious to nucleoside/tide Impervious to nucleoside/tide
analogue-based therapyanalogue-based therapy
Sits in cell for life of cellSits in cell for life of cell– up to 10 years in immune up to 10 years in immune
tolerant or inactive statetolerant or inactive state
Clearance based onClearance based on immune driven hepatocyte immune driven hepatocyte clearance clearance
or cell deathor cell death
Goals of treatment Goals of treatment
Suppression of HBV DNASuppression of HBV DNA– Goal is undetectableGoal is undetectable
Normal ALT Normal ALT – No inflammation or ongoing liver injuryNo inflammation or ongoing liver injury
Convert from active phase to inactiveConvert from active phase to inactive– HBeAG positive HBeAG positive negative and HBeAb pos. negative and HBeAb pos.
Hepatitis B – Hepatitis B – what every GI nurse what every GI nurse should knowshould know
EpidemiologyEpidemiologyModes of transmissionModes of transmissionRole of Hepatitis B vaccineRole of Hepatitis B vaccineNatural History Natural History Interpretation of serologyInterpretation of serologyIndications for treatment Indications for treatment Newer drugs available for treatmentNewer drugs available for treatmentImportance of Importance of ongoing follow up ongoing follow up
– Defined treatment Defined treatment duration duration
Nucleoside and Nucleoside and nucleotide analogsnucleotide analogs– Currently the Rx of choice Currently the Rx of choice
– Minimal SE Minimal SE
– Possibility of resistant Possibility of resistant mutantsmutants
– MOAMOASupresses but does not Supresses but does not eliminate the viruseliminate the virus
– Treatment indefiniteTreatment indefinite
Arauz-Ruiz P, et al. J Gen Virol. 2002;83:2059-2073. Bell SJ, et al. J Clin Virol. 2005;32:122-127.Chu CJ, et al. Gastroenterology. 2003;125:444-451. Kidd-Ljunggren K, et al. J Gen Virol. 2002;83:1267-1280. Keeffe EB, et al. Clin Gastroenterol Hepatol. 2004;2:87-106.
A, B, C,D, G
F
A, D, E
B, C
AG D
H, F
Global Distribution of the 8 HBV Global Distribution of the 8 HBV GenotypesGenotypes
D
A, B, C, D
Impact of HBV Genotype on Impact of HBV Genotype on Disease ProgressionDisease Progression
Genotype CGenotype C– severe liver diseasesevere liver disease– HCC HCC
Genotype BGenotype B– Seroconversion from HBeAg -> Seroconversion from HBeAg ->
anti-HBe at younger ageanti-HBe at younger age
Genotypes A and BGenotypes A and B– Increased response to Increased response to
Peginterferon alfa-2aPeginterferon alfa-2a
Keeffe EB, et al. Clin Gastroenterol Hepatol. 2006;4:936-962.
HBV Genotyping Line Probe Assay
marker line conj. control amp. control
Genotype A
Genotype B
Genotype C
Genotype D
Genotype E
Genotype F
Genotype G
123456789
10111213141516
Treatment Treatment DrugDrug PotencyPotency ResistanceResistance FDA approvedFDA approved
LamivudineLamivudine ++++ 20% at 1 yr; 20% at 1 yr;
70% at yr 5 70% at yr 5
YesYes
AdefovirAdefovir ++ 3% at 2 yr3% at 2 yr
28% at 5 yr28% at 5 yr
YesYes
EntecavirEntecavir ++++++++ <2% at 4 yr*<2% at 4 yr*
TelbivudineTelbivudine ++++++ 4% at one yr4% at one yr
11-25% at year 211-25% at year 2
yesyes
EmtricitabineEmtricitabine ++++ Similar to lamivudineSimilar to lamivudine Not yetNot yet
Hepatitis BHepatitis B
EpidemiologyEpidemiology
Modes of transmissionModes of transmission
Role of Hepatitis B vaccineRole of Hepatitis B vaccine
Natural History Natural History
Interpretation of serologyInterpretation of serology
Indications for treatment Indications for treatment
Newer drugsNewer drugs
Importance of Importance of
ongoing follow upongoing follow up
Importance of follow upImportance of follow up
To monitor for progression of diseaseTo monitor for progression of disease– To monitor those in inactive phases and To monitor those in inactive phases and – To recommend treatment in active phasesTo recommend treatment in active phases
Treament Treament – Monitor for efficacyMonitor for efficacy– Monitor for resistanceMonitor for resistance– monitor for toxicitymonitor for toxicity
To screen patients at high risk for HCC To screen patients at high risk for HCC regularly.regularly.
1. Check ALT every 1. Check ALT every 3-6 3-6 months. months.
2. If ALT increases –2. If ALT increases –check HBV DNAcheck HBV DNAWork up further Work up further Consider treatment or Consider treatment or biopsybiopsy
3. Screen for HCC in high 3. Screen for HCC in high risk patientsrisk patients
--Inactive HBsAg Inactive HBsAg carriercarrier::
1. Check ALT every 1. Check ALT every 6 – 126 – 12 monthsmonths
2. If ALT increases2. If ALT increasesCheck HBV DNA Check HBV DNA work up furtherwork up furtherconsider biopsy and consider biopsy and treatmenttreatment
3. Screen for HCC in high 3. Screen for HCC in high risk patients.risk patients.
Screening for HCCScreening for HCC
Ultrasound and AFPUltrasound and AFP– AFP every 6 months and AFP every 6 months and – Ultrasound every 6 – 12 monthsUltrasound every 6 – 12 months
Screen high risk patients: Screen high risk patients: – Family history of HCCFamily history of HCC– men over 40, women over 50men over 40, women over 50– patients with chronic hepatitis with high viral patients with chronic hepatitis with high viral
load load – patients with cirrhosis. patients with cirrhosis.
““You can stab it with your You can stab it with your steely anti-virals but you just steely anti-virals but you just